Loading clinical trials...

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression: a Randomized, Double-blind, Placebo-controlled Trial

NCT02726659•London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

View on ClinicalTrials.gov

Summary

The investigators will conduct a 6-week, randomized, double-blind, placebo-controlled trial of celecoxib as an add-on treatment to the mood stabilizer among women with bipolar I or II postpartum depression. Women who are taking a mood stabilizer for treatment of bipolar disorder in the postpartum treatment will receive either a placebo or celecoxib add-on treatment. Patients will be monitored regularly to assess psychiatric symptoms and side effects. The investigators aim to evaluate the potential antidepressant effect of celecoxib in bipolar postpartum depression.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•women aged 18-45 who are within 3 months of delivering a healthy, term (37 to 40 weeks) singleton
•diagnosis of bipolar postpartum depression - depressed with peripartum onset
•have a 17-item Hamilton Rating Scale for Depression score of \>18
•have failed to respond to an adequate trial of the mood stabilizer
•are currently not on any psychotropic drug except a mood stabilizer (lithium, lamotrigine or quetiapine)
•are able to communicate (written and oral) in English and capable of giving consent

Exclusion Criteria

•current major depressive episode of more than 6 months duration
•a current comorbid psychiatric disorder
•history of alcohol or substance abuse within the 12 months before screening
•concurrent psychotherapy
•high risk for suicide (actively suicidal or a score of = 3 on item #3 on HAM-D)
•current hepatic, renal, or cardiac disease, chronic pain, coagulation disorders, esophageal or gastro duodenal ulceration within the previous 30 days
•known immediate-type hypersensitivity to COX-2 inhibitors, sulfonamides, ibuprofen, or diclofenac
•breastfeeding mothers

Locations (1)

Parkwood Institute, Mental Health Care Buildling

London, Ontario, Canada

Key Dates

Start Date

May 1, 2016

Primary Completion Date

January 16, 2019

Completion Date

January 16, 2019

Last Updated

January 20, 2022

Enrollment

ACTUAL participants

Conditions

Bipolar DisorderPostpartum Depression

Interventions

Celecoxib

DRUG

Placebo

DRUG

University of Iowa Interventional Psychiatry Service Patient Registry

NCT04480918

Treatment Resistant DepressionMajor Depressive Episode+5 more

View study

RECRUITINGPHASE3

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

NCT07140913

ManiaBipolar Disorder

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression

Inclusion Criteria

Exclusion Criteria

University of Iowa Interventional Psychiatry Service Patient Registry

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

The Mom and Infant Outcomes (MOMI) Study

Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations

CBT-CP for Veterans With SMI

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)